Aurora, CO
OncoVerity focuses on optimizing and advancing the development of cusatuzumab, a novel anti-CD70 antibody.
oncoverity.comThese are collections OncoVerity is a part of. Click on the collection name to view similar companies.
Series A
$14,000,000
Series A
$30,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on OncoVerity.